Inari Medical, Inc. to Post Q3 2024 Earnings of ($0.08) Per Share, Leerink Partnrs Forecasts (NASDAQ:NARI)

Inari Medical, Inc. (NASDAQ:NARI) – Analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for Inari Medical in a report issued on Tuesday, September 3rd. Leerink Partnrs analyst M. Kratky forecasts that the company will post earnings per share of ($0.08) for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.75) per share. Leerink Partnrs also issued estimates for Inari Medical’s Q4 2024 earnings at ($0.03) EPS, Q1 2025 earnings at $0.01 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.06 EPS and FY2026 earnings at $0.37 EPS.

Other equities analysts also recently issued research reports about the stock. Robert W. Baird reduced their target price on shares of Inari Medical from $65.00 to $63.00 and set an “outperform” rating for the company in a research note on Wednesday, July 31st. William Blair started coverage on shares of Inari Medical in a research note on Thursday, July 25th. They issued an “outperform” rating for the company. Wells Fargo & Company reduced their target price on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on shares of Inari Medical in a research note on Friday, August 9th. They issued a “buy” rating and a $68.00 target price for the company. Finally, Truist Financial reaffirmed a “hold” rating and set a $55.00 price objective (down previously from $60.00) on shares of Inari Medical in a research note on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.50.

Inari Medical Stock Down 3.2 %

NARI opened at $41.68 on Wednesday. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of -101.66 and a beta of 1.00. The firm has a 50-day moving average price of $49.39 and a 200-day moving average price of $46.77. Inari Medical has a twelve month low of $36.73 and a twelve month high of $69.40.

Institutional Investors Weigh In On Inari Medical

Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its holdings in shares of Inari Medical by 7.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 596,007 shares of the company’s stock worth $38,693,000 after acquiring an additional 41,555 shares during the last quarter. Norges Bank bought a new stake in Inari Medical during the 4th quarter valued at $29,491,000. Motley Fool Asset Management LLC raised its holdings in Inari Medical by 46.2% during the 1st quarter. Motley Fool Asset Management LLC now owns 64,677 shares of the company’s stock valued at $3,103,000 after buying an additional 20,438 shares during the last quarter. Bamco Inc. NY raised its holdings in Inari Medical by 27.4% during the 1st quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock valued at $37,288,000 after buying an additional 167,000 shares during the last quarter. Finally, Point72 Europe London LLP raised its holdings in Inari Medical by 91.8% during the 4th quarter. Point72 Europe London LLP now owns 332,202 shares of the company’s stock valued at $21,567,000 after buying an additional 158,997 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, CFO Mitch C. Hill sold 5,000 shares of Inari Medical stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $47.60, for a total transaction of $238,000.00. Following the completion of the sale, the chief financial officer now directly owns 181,294 shares in the company, valued at $8,629,594.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $50.08, for a total transaction of $150,240.00. Following the completion of the sale, the chief executive officer now directly owns 462,474 shares in the company, valued at $23,160,697.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Mitch C. Hill sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $47.60, for a total transaction of $238,000.00. Following the completion of the sale, the chief financial officer now owns 181,294 shares of the company’s stock, valued at $8,629,594.40. The disclosure for this sale can be found here. Insiders sold a total of 117,780 shares of company stock worth $6,393,074 over the last three months. 10.60% of the stock is owned by insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.